xepos 250 mg granulado para suspensão oral - Результати пошуку

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

boots day cold & flu relief oral solution

the boots company plc - paracetamol; pseudoephedrine hydrochloride; pholcodine - oral solution - 33.33mg/1ml ; 2mg/1ml ; 333.33microgram/1ml

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

paracetamol 10 mg/ml solution for infusion

fresenius kabi deutschland gmbh - paracetamol - solution for infusion - 10 milligram(s)/millilitre - anilides; paracetamol

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

paracetamol 10 mg/ml solution for infusion

fresenius kabi deutschland gmbh - paracetamol - solution for infusion - 10 milligram(s)/millilitre - anilides; paracetamol

Уганда - англійська - National Drug Authority

febricol tablets 500mg / 30mg /2mg oral solid ordinary tablets

xepa soul pattison (m) sdn bhd - paracetamol / pseudoephedrine / chlorpheniramine - oral solid ordinary tablets - 500mg / 30mg /2mg

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

augmentin duo 400 powder for oral liquid bottle

aspen pharmacare australia pty ltd - clavulanic acid, quantity: 11.4 mg/ml; amoxicillin, quantity: 80 mg/ml - oral liquid, powder for - excipient ingredients: silicon dioxide; succinic acid; colloidal anhydrous silica; aspartame; xanthan gum; hypromellose; flavour - augmentin duo 400 oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology). skin and skin structure infections: urinary tract infections (complicated and uncomplicated): upper respiratory tract infections including sinusitis, otitis media: lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is good reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo 400, should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo 400.

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

paracetamol 10 mg/ml solution for infusion

fresenius kabi limited - paracetamol - solution for infusion - 10 mg/ml - analgesics and antipyretics

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

paracetamol 10 mg/ml solution for infusion

fresenius kabi limited - paracetamol - solution for infusion - 10 mg/ml - analgesics and antipyretics

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

paracetamol 10mg/ml solution for infusion

maco pharma (uk) ltd - paracetamol - solution for infusion - 10 milligram(s)/millilitre - anilides; paracetamol